These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38642125)

  • 21. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Robotic pelvic exenteration and extended pelvic resections for locally advanced or synchronous rectal and urological malignancy.
    Williams M; Perera M; Nouhaud FX; Coughlin G
    Investig Clin Urol; 2021 Jan; 62(1):111-120. PubMed ID: 33381928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resection of synchronous liver metastases between radiotherapy and definitive surgery for locally advanced rectal cancer: short-term surgical outcomes, overall survival and recurrence-free survival.
    Labori KJ; Guren MG; Brudvik KW; Røsok BI; Waage A; Nesbakken A; Larsen S; Dueland S; Edwin B; Bjørnbeth BA
    Colorectal Dis; 2017 Aug; 19(8):731-738. PubMed ID: 28181384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 26. Neoadjuvant therapy and mini-invasive total mesorectal excision for rectal cancer: feasibility and outcome analysis from a single institution prospectively collected data base.
    Grosso F; Mandalà M; Maglione V; Berretta L; Mariani N; Rossi M; Piovano PL; Drago D; Summa M; Franzone P; Musante F; Spinoglio G
    Tumori; 2012 Nov; 98(6):689-95. PubMed ID: 23389353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment.
    Sanfilippo NJ; Crane CH; Skibber J; Feig B; Abbruzzese JL; Curley S; Vauthey JN; Ellis LM; Hoff P; Wolff RA; Brown TD; Cleary K; Wong A; Phan T; Janjan NA
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):176-83. PubMed ID: 11516868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Exploration on neoadjuvant chemoradiation in the treatment for locally advanced low rectal cancer].
    Yu BM; Zhang M; Peng LH; Bian GW; Wu WQ; Chen LW; Fu J; Fei CS
    Zhonghua Wai Ke Za Zhi; 2009 Oct; 47(20):1540-3. PubMed ID: 20092741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
    Falchook AD; Basak R; Mohiuddin JJ; Chen RC
    Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant versus neoadjuvant androgen deprivation with radiotherapy for prostate cancer: does sequencing matter?
    Weller MA; Kupelian PA; Reddy CA; Stephans KL; Tendulkar RD
    Clin Genitourin Cancer; 2015 Jun; 13(3):e183-9. PubMed ID: 25660127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surgery for locally recurrent rectal cancer in the era of total mesorectal excision: is there still a chance for cure?
    Rahbari NN; Ulrich AB; Bruckner T; Münter M; Nickles A; Contin P; Löffler T; Reissfelder C; Koch M; Büchler MW; Weitz J
    Ann Surg; 2011 Mar; 253(3):522-33. PubMed ID: 21209587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of high-dose rate (HDR) brachytherapy for patients with prostate cancer and history of prior chemoradiation for rectal cancer: A case series.
    Thomas H; Chen JJ; Abdul-Baki H; Sabbagh A; Shaheen H; Chau OW; Malik N; Ayoub A; Hassanzadeh C; Hsu IC; Mohamad O
    Brachytherapy; 2024; 23(2):173-178. PubMed ID: 38160102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of locally advanced synchronous colorectal and prostate cancers: A case report.
    Tey YQ; Ravi K; Chong CS; Chiong E; Ho J; Tey JCS; Ho F
    Medicine (Baltimore); 2020 May; 99(22):e20336. PubMed ID: 32481410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal Cancer Surgery multicenter observational trial.
    Garlipp B; Ptok H; Schmidt U; Meyer F; Gastinger I; Lippert H
    Langenbecks Arch Surg; 2010 Nov; 395(8):1031-8. PubMed ID: 20711786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer.
    Heymann JJ; Benson MC; O'Toole KM; Malyszko B; Brody R; Vecchio D; Schiff PB; Mansukhani MM; Ennis RD
    J Clin Oncol; 2007 Jan; 25(1):77-84. PubMed ID: 17194907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beyond total mesorectal excision in locally advanced rectal cancer with organ or pelvic side-wall involvement.
    Mariathasan AB; Boye K; Giercksky KE; Brennhovd B; Gullestad HP; Emblemsvåg HL; Grøholt KK; Dueland S; Flatmark K; Larsen SG
    Eur J Surg Oncol; 2018 Aug; 44(8):1226-1232. PubMed ID: 29691115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
    Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
    Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.